- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Submit raw data linked to CT result: CDSCO Panel Tells Akum Pharma on Azelnidipine, Metoprolol FDC drug
New Delhi: Based on the justification presented by Akum Pharmaceutical with respect to the clinical trial results of the fixed-dose combination (FDC) drug Azelnidipine plus Metoprolol, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined the firm to submit the raw data of the clinical trial.
This came after the firm presented its proposal along with clarification/justification with respect to clinical trial results of the FDC cardiovascular drug Azelnidipine 8mg/8mg/16mg/16mg)plus Metoprolol (25mg/ 50mg/25mg/50mg) sustained released (SR) tablet.
Azelnidipine is a medicine used to treat high blood pressure. It belongs to a group of medicines that block the calcium channels in the blood vessels. It works by relaxing the blood vessels in patients with high blood pressure.
Azelnidipine inhibits trans-membrane Ca2+ influx through the voltage-dependent channels of smooth muscles in vascular walls. Ca2+ channels are classified into various categories, including L-type, T-type, N-type, P/Q-type, and R-type Ca2+ channels.
Metoprolol is a beta-1-adrenergic receptor inhibitor specific to cardiac cells with negligible effect on beta-2 receptors. Metoprolol is a medication that lowers your blood pressure and heart rate, making it easier for the heart to pump blood to the rest of your body. It treats high blood pressure. It also prevents chest pain or further damage after a heart attack.
Earlier, the Medical Dialogues Team had reported that the Central Drug Standard Control Organisation (CDSCO) panel had opined Akum Pharmaceuticals to submit detailed clarification/justification regarding the study of the fixed-dose combination drug (FDC) Azelnidipine plus Metoprolol tablet.
In continuation, at the recent SEC meeting for the Cardiovascular and renal held on 11 October 2023, the expert panel reviewed the proposal presented by Akum Pharmaceuticals along with clarification or justification with respect to clinical trial results of the FDC Azelnidipine plus Metoprolol (SR) tablet.
After detailed deliberation, the committee opined that the firm should submit raw data from the clinical trial to the CDSCO for review by the committee.
Also Read:Submit Phase III CT Protocol: CDSCO Panel Tells Glenmark Pharmaceuticals on Antidiabetic FDC
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.